Cargando…

Safety and Efficacy of Degradable Starch Microspheres Transcatheter Arterial Chemoembolization (DSM-TACE) in the Downstaging of Intermediate-Stage Hepatocellular Carcinoma (HCC) in Patients With a Child-Pugh Score of 8-9

According to the EASL Guidelines for the management of hepatocellular carcinoma, transcatheter arterial chemoembolization is the first-line treatment recommended for intermediate-stage HCC. Furthermore, it is widely accepted that patients beyond the Milan criteria can be considered for a liver trans...

Descripción completa

Detalles Bibliográficos
Autores principales: Minici, Roberto, Ammendola, Michele, Manti, Francesco, Siciliano, Maria Anna, Minici, Marco, Komaei, Iman, Currò, Giuseppe, Laganà, Domenico
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8060654/
https://www.ncbi.nlm.nih.gov/pubmed/33897422
http://dx.doi.org/10.3389/fphar.2021.634087
_version_ 1783681408113311744
author Minici, Roberto
Ammendola, Michele
Manti, Francesco
Siciliano, Maria Anna
Minici, Marco
Komaei, Iman
Currò, Giuseppe
Laganà, Domenico
author_facet Minici, Roberto
Ammendola, Michele
Manti, Francesco
Siciliano, Maria Anna
Minici, Marco
Komaei, Iman
Currò, Giuseppe
Laganà, Domenico
author_sort Minici, Roberto
collection PubMed
description According to the EASL Guidelines for the management of hepatocellular carcinoma, transcatheter arterial chemoembolization is the first-line treatment recommended for intermediate-stage HCC. Furthermore, it is widely accepted that patients beyond the Milan criteria can be considered for a liver transplant after successful downstaging to within the Milan criteria. Response to downstaging treatments significantly influences not just drop-outs, but also the rate of post-transplantation tumor recurrences. TACE with degradable starch microspheres represents an alternative to conventional TACE with lipiodol and TACE with drug-eluting beads, and it leads to transient arterial occlusion allowing lower activation of hypoxia-inducible factors and less release of vascular endothelial growth factor, a promoter of neoangiogenesis, tumor proliferation, and metastatic growth. In patients with intermediate-stage HCC and a Child-Pugh score of 8 or 9, life expectancy may be dominated by cirrhotic liver dysfunction, rather than by the tumor progression itself; hence, locoregional treatments might also be detrimental, precipitating liver dysfunction to an extent that survival is shortened rather than prolonged. Data on tolerability, toxicity, and effectiveness of DSM-TACE are limited but encouraging. Between January 2015 and October 2020, 50 consecutive patients with intermediate-stage hepatocellular carcinoma and a Child-Pugh score of 8/9, who had undergone DSM-TACE as the first-line treatment, were eligible for the study. A total of 142 DSM-TACEs were performed, with a mean number of 2.84 procedures per patient. The mean time-to-downstaging was 19.2 months, with six patients successfully downstaged. OS was about 100% at six months, 81.8% at 12 months, and 50% at 24 months. Twenty-two patients experienced adverse events after chemoembolization. The median OS and safety of DSM-TACE in this study are comparable with other published investigations in this field. Furthermore, 12% of patients were successfully downstaged. Hence, the results of the current investigation demonstrate that DSM-TACE is effective and safe in intermediate-stage HCC, achieving an interesting downstaging rate. Such data were observed in the population subset with a Child-Pugh score of 8 or 9, in which life expectancy may be determined by cirrhotic liver dysfunction, so the achievement of a balance between the safety and efficacy profile of the TACE treatment is crucial.
format Online
Article
Text
id pubmed-8060654
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-80606542021-04-23 Safety and Efficacy of Degradable Starch Microspheres Transcatheter Arterial Chemoembolization (DSM-TACE) in the Downstaging of Intermediate-Stage Hepatocellular Carcinoma (HCC) in Patients With a Child-Pugh Score of 8-9 Minici, Roberto Ammendola, Michele Manti, Francesco Siciliano, Maria Anna Minici, Marco Komaei, Iman Currò, Giuseppe Laganà, Domenico Front Pharmacol Pharmacology According to the EASL Guidelines for the management of hepatocellular carcinoma, transcatheter arterial chemoembolization is the first-line treatment recommended for intermediate-stage HCC. Furthermore, it is widely accepted that patients beyond the Milan criteria can be considered for a liver transplant after successful downstaging to within the Milan criteria. Response to downstaging treatments significantly influences not just drop-outs, but also the rate of post-transplantation tumor recurrences. TACE with degradable starch microspheres represents an alternative to conventional TACE with lipiodol and TACE with drug-eluting beads, and it leads to transient arterial occlusion allowing lower activation of hypoxia-inducible factors and less release of vascular endothelial growth factor, a promoter of neoangiogenesis, tumor proliferation, and metastatic growth. In patients with intermediate-stage HCC and a Child-Pugh score of 8 or 9, life expectancy may be dominated by cirrhotic liver dysfunction, rather than by the tumor progression itself; hence, locoregional treatments might also be detrimental, precipitating liver dysfunction to an extent that survival is shortened rather than prolonged. Data on tolerability, toxicity, and effectiveness of DSM-TACE are limited but encouraging. Between January 2015 and October 2020, 50 consecutive patients with intermediate-stage hepatocellular carcinoma and a Child-Pugh score of 8/9, who had undergone DSM-TACE as the first-line treatment, were eligible for the study. A total of 142 DSM-TACEs were performed, with a mean number of 2.84 procedures per patient. The mean time-to-downstaging was 19.2 months, with six patients successfully downstaged. OS was about 100% at six months, 81.8% at 12 months, and 50% at 24 months. Twenty-two patients experienced adverse events after chemoembolization. The median OS and safety of DSM-TACE in this study are comparable with other published investigations in this field. Furthermore, 12% of patients were successfully downstaged. Hence, the results of the current investigation demonstrate that DSM-TACE is effective and safe in intermediate-stage HCC, achieving an interesting downstaging rate. Such data were observed in the population subset with a Child-Pugh score of 8 or 9, in which life expectancy may be determined by cirrhotic liver dysfunction, so the achievement of a balance between the safety and efficacy profile of the TACE treatment is crucial. Frontiers Media S.A. 2021-04-08 /pmc/articles/PMC8060654/ /pubmed/33897422 http://dx.doi.org/10.3389/fphar.2021.634087 Text en Copyright © 2021 Minici, Ammendola, Manti, Siciliano, Minici, Komaei, Currò and Laganà. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Minici, Roberto
Ammendola, Michele
Manti, Francesco
Siciliano, Maria Anna
Minici, Marco
Komaei, Iman
Currò, Giuseppe
Laganà, Domenico
Safety and Efficacy of Degradable Starch Microspheres Transcatheter Arterial Chemoembolization (DSM-TACE) in the Downstaging of Intermediate-Stage Hepatocellular Carcinoma (HCC) in Patients With a Child-Pugh Score of 8-9
title Safety and Efficacy of Degradable Starch Microspheres Transcatheter Arterial Chemoembolization (DSM-TACE) in the Downstaging of Intermediate-Stage Hepatocellular Carcinoma (HCC) in Patients With a Child-Pugh Score of 8-9
title_full Safety and Efficacy of Degradable Starch Microspheres Transcatheter Arterial Chemoembolization (DSM-TACE) in the Downstaging of Intermediate-Stage Hepatocellular Carcinoma (HCC) in Patients With a Child-Pugh Score of 8-9
title_fullStr Safety and Efficacy of Degradable Starch Microspheres Transcatheter Arterial Chemoembolization (DSM-TACE) in the Downstaging of Intermediate-Stage Hepatocellular Carcinoma (HCC) in Patients With a Child-Pugh Score of 8-9
title_full_unstemmed Safety and Efficacy of Degradable Starch Microspheres Transcatheter Arterial Chemoembolization (DSM-TACE) in the Downstaging of Intermediate-Stage Hepatocellular Carcinoma (HCC) in Patients With a Child-Pugh Score of 8-9
title_short Safety and Efficacy of Degradable Starch Microspheres Transcatheter Arterial Chemoembolization (DSM-TACE) in the Downstaging of Intermediate-Stage Hepatocellular Carcinoma (HCC) in Patients With a Child-Pugh Score of 8-9
title_sort safety and efficacy of degradable starch microspheres transcatheter arterial chemoembolization (dsm-tace) in the downstaging of intermediate-stage hepatocellular carcinoma (hcc) in patients with a child-pugh score of 8-9
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8060654/
https://www.ncbi.nlm.nih.gov/pubmed/33897422
http://dx.doi.org/10.3389/fphar.2021.634087
work_keys_str_mv AT miniciroberto safetyandefficacyofdegradablestarchmicrospherestranscatheterarterialchemoembolizationdsmtaceinthedownstagingofintermediatestagehepatocellularcarcinomahccinpatientswithachildpughscoreof89
AT ammendolamichele safetyandefficacyofdegradablestarchmicrospherestranscatheterarterialchemoembolizationdsmtaceinthedownstagingofintermediatestagehepatocellularcarcinomahccinpatientswithachildpughscoreof89
AT mantifrancesco safetyandefficacyofdegradablestarchmicrospherestranscatheterarterialchemoembolizationdsmtaceinthedownstagingofintermediatestagehepatocellularcarcinomahccinpatientswithachildpughscoreof89
AT sicilianomariaanna safetyandefficacyofdegradablestarchmicrospherestranscatheterarterialchemoembolizationdsmtaceinthedownstagingofintermediatestagehepatocellularcarcinomahccinpatientswithachildpughscoreof89
AT minicimarco safetyandefficacyofdegradablestarchmicrospherestranscatheterarterialchemoembolizationdsmtaceinthedownstagingofintermediatestagehepatocellularcarcinomahccinpatientswithachildpughscoreof89
AT komaeiiman safetyandefficacyofdegradablestarchmicrospherestranscatheterarterialchemoembolizationdsmtaceinthedownstagingofintermediatestagehepatocellularcarcinomahccinpatientswithachildpughscoreof89
AT currogiuseppe safetyandefficacyofdegradablestarchmicrospherestranscatheterarterialchemoembolizationdsmtaceinthedownstagingofintermediatestagehepatocellularcarcinomahccinpatientswithachildpughscoreof89
AT laganadomenico safetyandefficacyofdegradablestarchmicrospherestranscatheterarterialchemoembolizationdsmtaceinthedownstagingofintermediatestagehepatocellularcarcinomahccinpatientswithachildpughscoreof89